Physician profile
Keith Schumann
NPI 1982612792
$371.21
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $150 · 2021: $26.82 · 2022: $67.23.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $232.22 | 2019-2020 | |
| Incyte Corporation | $67.23 | 2022 | |
| Abbvie INC. | $26.82 | 2021 | |
| Greenwich Biosciences, INC. | $16.95 | 2019 | |
| Merz North America, INC. | $14.42 | 2019 | |
| Merck Sharp & Dohme LLC | $13.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Schumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.